HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sephora At Kohl’s Lineup Released: ‘Some Of The Most Relevant And Exciting Brands In The Industry’

Executive Summary

The curated assortment of prestige beauty brands, tended by trained beauty advisors, will launch in 200 Kohl’s stores across the US, as well as Kohls.com, in August.

You may also be interested in...



Natura Considers Avon Separation; LVMH Highlights Sephora Growth In 2023; Beauty News In Brief

Splitting off Avon as its own publicly traded company would unlock shareholder value and provide shareholders with greater visibility into the entities’ performance and potential, Natura says. Sephora sales fueled 20% reported growth in LVMH’s Selective Retailing business in 2023. More beauty news.

Kohl’s Anticipates $2Bn In Sales By 2025 From ‘Game Changing’ Sephora Installations

Kohl’s reports its Sephora at Kohl’s beauty store-within-store has brought 1 million new customers – largely young and diverse – since it launched last August, with $2bn in sales targeted by 2025.

CVS Piloting Skin Care Centers, The Latest Prestige Cosmetics Shop-In-Shop Experiment

CVS is trialing Skin Care Centers in three strategic locations, building on its BeautyIRL concept launched in 2018. Featuring prestige brands and L’Oréal-trained beauty advisors, CVS Skin Care Centers follows Walmart’s launch of BEAUTYSPACE installations in March and moves from Kohl’s and Target mid-pandemic to wow shoppers with curated prestige beauty assortments.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel